93 completed, 34 terminated, 24 unknown, 20 active not recruiting. 200 Phase 2, 72 Phase 1, 3 Phase 3.
Follow Glioblastoma Multiforme: new trials by email Literature Review of Glioblastoma Multiforme trials Research Report on Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Ruxolitinib, Temozolomide, Radiation Therapy - Glioblastoma, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 190 | 2025-12-03 | 2026-10-02 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Biological G207 - Neoplasms, High Grade Glioma | Phase 2 | Withdrawn | Pediatric Brain Tumor Consortium | 2025-09-01 | 2026-02-10 | |
| Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate - Glioblastoma Multiforme, Relapse | Phase 2 | Recruiting | Université de Sherbrooke | 120 | 2025-08-01 | 2025-08-07 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM Haloperidol Tablets, Temozolomide - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Southern Medical University, China | 200 | 2024-12-01 | 2024-01-23 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
| TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ) - Glioblastoma Multiforme | Phase 2 | Unknown | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | 30 | 2024-04-30 | 2024-08-09 |
| T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Allogeneic cytomegalovirus-specific T cells, Pembrolizumab - Glioblastoma Multiforme, Astrocytoma, Grade IV | Phase 1 / Phase 2 | Active not recruiting | Queensland Institute of Medical Research | 58 | 2024-02-08 | 2026-06-26 |
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma Balstilimab, Botensilimab, Liposomal Doxorubicin - Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype | Phase 2 | Active not recruiting | Northwestern University | 25 | 2024-01-19 | 2026-09-29 |
| Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab APG-157 - Glioma, Glioblastoma Multiforme | Phase 1 / Phase 2 | Active not recruiting | Aveta Biomics, Inc. | 30 | 2023-12-13 | 2026-10-05 |
| A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma Chlorophyllin - Diffuse Glioma, Radionecrosis of Brain | Phase 2 | Recruiting | Tata Memorial Centre | 118 | 2023-11-13 | 2025-04-11 |
| Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells pH Measurement of in vivo tissue - Glioblastoma Multiforme, Glycolytic Index | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2023-09-06 | 2026-10-08 |
| A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment Keto Diet, Standard Anti-Cancer Diet - Glioblastoma Multiforme | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 170 | 2023-06-27 | 2026-08-05 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM NanO2TM, Placebo Saline Infusion - Glioblastoma Multiforme | Phase 2 | Active not recruiting | NuvOx LLC | 87 | 2023-03-31 | 2026-08-06 |
Showing 20 of 200. Sign in to see all of them.
Glioblastoma (200) · Glioma (59) · Brain Neoplasms (58) · Astrocytoma (30) · Gliosarcoma (23) · Recurrence (15) · Neoplasms (13) · Oligodendroglioma (10) · Central Nervous System Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (5) · Diffuse Intrinsic Pontine Glioma (5) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Central Nervous System Diseases (3) · Pancreatic Neoplasms (3)
Neoplasms, Germ Cell and Embryonal (200) · Neoplasms, Glandular and Epithelial (200) · Neuroectodermal Tumors (200) · Neoplasms by Histologic Type (199) · Neoplasms, Neuroepithelial (199) · Neoplasms, Nerve Tissue (198) · Neoplasms (187) · Astrocytoma (170) · Glioma (141) · Neoplasms by Site (69) · Nervous System Diseases (63) · Nervous System Neoplasms (61) · Brain Diseases (59) · Central Nervous System Diseases (58) · Central Nervous System Neoplasms (55)
Temozolomide (66) · Bevacizumab (38) · Radiotherapy (26) · Irinotecan (9) · Carmustine (7) · Lomustine (7) · Surgical Procedures, Operative (7) · Carboplatin (6) · Radiation (6) · Radiosurgery (5) · Sunitinib (4) · pembrolizumab (4) · Cetuximab (3) · Dianhydrogalactitol (3) · Disulfiram (3)
M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (6) · Duke University (4) · Northwell Health (4) · Hoffmann-La Roche (3) · Kintara Therapeutics, Inc. (3) · Myrexis Inc. (3) · SCRI Development Innovations, LLC (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · University of Florida (3) · AHS Cancer Control Alberta (2) · Baylor College of Medicine (2) · Brown University (2) · Clinica Universidad de Navarra, Universidad de Navarra (2) · Copenhagen University Hospital, Rigshospitalet (2)
United States (130) · Canada (12) · Germany (10) · Italy (7) · Australia (6) · China (6) · France (6) · Spain (6) · United Kingdom (6) · Israel (5) · Austria (4) · Denmark (4) · India (3) · Taiwan (3) · Czechia (2)
John Boockvar, MD (3) · Allen K Sills, MD (2) · Andrew Beelen, MD (2) · Annick Desjardins, MD, FRCPC (2) · Charles Conrad, MD (2) · David Fortin, MD (2) · David Reardon, MD (2) · Howard Safran, MD (2) · John Fiveash, MD (2) · Katherine B Peters, MD, PhD (2) · Louis B. Nabors, III, M.D. (2) · Mark R. Gilbert (2) · Marta Penas-Prado, MD (2)
PMID 15809479, PMID 16648043, PMID 16877732, PMID 18981465, PMID 19075262, PMID 19534336, PMID 19760366, PMID 20564147, PMID 20615924, PMID 20729242, PMID 21499132, PMID 21792866, PMID 22284691, PMID 22931705, PMID 23388562, PMID 23404447, PMID 23566417, PMID 23844725, PMID 24026531, PMID 24256396, PMID 24311637, PMID 24344045, PMID 24947313, PMID 25239666, PMID 25915780, PMID 25944802, PMID 26025933, PMID 26106073, PMID 26541586, PMID 26843484, PMID 26951379, PMID 26976423, PMID 27252174, PMID 27580889, PMID 28291390, PMID 28499389, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29016998, PMID 29036345, PMID 29121274, PMID 29472310, PMID 29660005, PMID 29666296, PMID 30522967, PMID 30786188, PMID 31189049, PMID 31290996, PMID 32285998
2009 (2), 2014 (2), 2016 (1), 2018 (1), 2019 (1), 2023 (1), R01CA175517 (1), R01CA276919 (1), R21CA256421 (1), U01CA062475 (1), U01CA236215 (1), UM1CA081457 (1)